Related Experiment Video
Updated: May 12, 2026

Profiling Ubiquitin and Ubiquitin-like Dependent Post-translational Modifications and Identification of Significant Alterations
Published on: November 7, 2019
Gemcitabine induced hemolytic uremic syndrome
Seyed-Ali Sadjadi1, Pavan Annamaraju
1Nephrology Section, Jerry L. Pettis Memorial Veterans Medical Center, Loma Linda, CA, U.S.A ; Loma Linda University School of Medicine, Loma Linda, CA, U.S.A.
Background:
Gemcitabine is frequently used for the treatment of many cancers. Not infrequently it leads to development of hemolytic uremic syndrome, presenting with hemolytic anemia, acute kidney injury and occasionally peripheral edema, livedo reticularis and digital necrosis.
Case Report:
A 78 year old man with non-small cell lung cancer developed uremic syndrome following treatment with multiple chemotherapy agents including gemcitabine. He was treated aggressively with hemodialysis and plasmapheresis. Initially he responded but upon attempts at decreasing the frequency of plasmapheresis, lactate dehydrogenase increased and platelet count decreased, indicating continuing hemolysis. Hemolysis responded to splenectomy but he continued to require hemodialysis treatment.
Conclusions:
Although many cases of gemcitabine induced HUS have been reported, its cause and pathogenesis remain unclear and it should be used with caution. Frequent monitoring of renal function and close observation of the patient are essential.
Related Concept Videos
Hypersensitivity Reactions: Cytolytic Reactions
Cytomegalovirus Disease
Hemodialysis II: Procedure and Complications
Continuous Renal Replacement Therapy
Acute Kidney Injury IV: Diagnostic Studies and Prevention